
1	Polymorphism of Cocrystals: The Promiscuous Behavior of Agomelatine
2	
3	
4	
5	
6 7 9 10 11 12 13	Rafel Prohens, ^{*,†} Rafael Barbas, [†] Anna Portell, [†] Mercè Font-Bardia, [‡] Xavier Alcobé ^{,‡} and Cristina Puigjaner ^{*,†}
14 15 16 17 18 19 20	
21 22 23 24 25 26 27 28 29 30 31 32	[†] Unitat de Polimorfisme i Calorimetria and [‡] Unitat de Difracció de Raigs X, Centres Científics i Tecnològics, Universitat de Barcelona, Baldiri Reixac 10, 08028 Barcelona, Spain

33 ABSTRACT:

34

35 It has been traditionally suggested that polymorphism of cocrystals is a

- 36 phenomenon seen less frequently than in monocomponent crystals. However, since the
- 37 research on cocrystals has recently experienced a big growth, the number of solved
- 38 structures of polymorphic cocrystals in the Cambridge Structural Database has increased,
- 39 which can help to understand better whether a lower impact of this phenomenon exists or
- 40 not in multicomponent crystals. In this paper we describe the cocrystal landscape of
- 41 agomelatine, a particularly promiscuous drug able to cocrystallize with up to nine different
- 42 coformers. Interestingly, two of those coformers have produced polymorphic cocrystals
- 43 during the screening, which converts agomelatine into a new example that questions the
- 44 traditional belief of the lesser impact of polymorphism in cocrystals and highlights the
- 45 importance of polymorphism studies in cocrystal screening. Our work is completed with
- 46 the determination of the crystal structures of the new forms from combined single crystal/
- 47 laboratory X-ray powder diffraction data.
- 48



- 49
- 50
- 51
- 52
- 53 54

56 **1. INTRODUCTION**

57

58 Polymorphism of active principle ingredients (API) is almost omnipresent.1 In fact, published data from

59 experimental screens suggest that 80–90% of organic compounds can exist in multiple crystalline forms

60 (polymorphs and solvates) and half of the organic compounds can be polymorphic.2 In recent years, the

- 61 number of new crystal forms for a drug has been much increased since the erruption of cocrystals in the
- 62 solid state arena, which offers many opportunities to modify their bulk properties, such as solubility,
- 63 bioavailability and stability. According to Butterhof et al.,3 the number of characterized polymorphs and
- 64 cocrystals in 2012 was 2050 and 3650, respectively. In 2010 Zaworotko et al.4 analyzed 38 polymorphic
- 65 cocrystals, revealing that in 35 polymorphic pairs polymorphism is the result of conformational
- 66 flexibility and/or structural changes in the packing.
- 67 Moreover, an exhaustive search in the literature by Aitipamula et al. in 20135 revealed a total of 110
- neutral polymorphic cocrystals. The lower propensity of cocrystals to exhibit polymorphism has been
- 69 then called into question, and probably a bigger corpus of crystallographic data will be required before
- the question can be reliably answered.6 Since multicomponent crystals are increasingly relevant in the
- 71 pharmaceutical industry with cocrystal screenings being routinely performed, a better understanding of
- 72 polymorphism of cocrystals is a real need. In this paper we intend to contribute new data in order to
- rich this relevant debate. Agomelatine (N-[2-(7-methoxynaphthalen-1-yl)ethyl]-acetamide) (Figure 1),
- vunder the trade name of Valdoxan or Melitor, is an effective drug for the treatment of major depressive
- disorders7 first produced by Servier pharmaceutical company in 2009. It has been reported to exist as
- six polymorphic modifications (Forms I–VI). The crystal structures of Forms I, II, and III have been
- determined8,9 by single and powder X-ray diffraction, and cocrystals with acetic acid, ethylene glycol,
- vrea, glycolic acid, isonicotinamide, and methyl 4-hydroxybenzoate have been synthesized and
- 79 structurally characterized.9,10
- 80 The pharmaceutical relevance of this compound together with the existence of a big number of different
- 81 multicomponent crystal modifications prompted us to study its cocrystal promiscuity in relation with the
- 82 presence of polymorphism. In this contribution, we take a step forward in the investigation of the solid-
- 83 state landscape of agomelatine by presenting new polymorphic cocrystals with acetic acid and
- 84 hydroquinone, together with cocrystals with pyruvic acid and oxalic acid.
- 85

86 2. MATERIALS AND METHODS

87

2.1. Synthesis of the New Crystal Forms. 2.1.1. Hydroquinone Cocrystal Ago-HQ Form I. 100 88 milligrams (0.41 mmol) of agomelatine and 45 mg (0.41 mmol) of hydroquinone were dissolved in 0.1 89 90 mL of acetone or ethyl acetate. Crystals suitable for single crystal X-ray diffraction (SCXRD) were 91 obtained after evaporation of the solvent at room temperature after 2 days (mp 81 °C). 92 93 2.1.2. Hydroquinone Cocrystal Ago-HQ Form II. Twenty milligrams (0.08 mmol) of agomelatine and 94 10 mg (0.09 mmol) of hydroquinone were grinded in a ball mill with the addition of one drop of 95 acetonitrile during 30 min at 30 Hz (mp 93 °C). 96 97 2.1.3. Oxalic Acid Cocrystal Ago-OA Form I. Twenty milligrams (0.08 mmol) of agomelatine and 7 mg (0.08 mmol) of oxalic acid were dissolved in 50 µL of isopropanol at 40 °C, and the solution was cooled 98 99 to room temperature in a closed vial. Crystals suitable for SCXRD were obtained after 1 day (mp 87°C). 100 101 2.1.4. Acetic Acid Cocrystal Ago-AA Form II. 80 milligrams (0.33 mmol) of agomelatine were dissolved in 50 µL of acetic acid at 45 °C, and the solution was cooled to room temperature in a closed 102 vial. Crystals suitable for SCXRD were obtained after 20 days (mp 65 °C). 103 104 105 2.1.5. Pyruvic Acid Cocrystal Ago-PA. 200 milligrams (0.82 mmol) of agomelatine were dissolved in 0.5 mL of pyruvic acid at 50 °C. The solution was cooled to 5 °C in a closed vial, and crystals suitable 106 107 for SCXRD were obtained after 5 days (mp 69 °C). 108 109 2.2. Methods. 2.2.1. Powder X-ray Diffraction (PXRD). Powder Xray diffraction patterns were obtained on a PANalytical X'Pert PRO MPD diffractometer in transmission configuration using Cu K α 1 + 2 110 111 radiation ($\lambda = 1.5418$ Å) with a focalizing elliptic mirror and a PIXcel detector working at a maximum 112 detector's active length of 3.347°. Capillary geometry has been used with samples placed in glass capillaries (Lindemman) of 0.5 mm of diameter measuring from 2 to 60° in 2 θ , with a step size of 113 0.026° and a total measuring time of 30 min. Flat geometry has been used for routine samples 114 sandwiched between low absorbing films (polyester of 3.6 µm of thickness) measuring 2theta/theta 115 116 scans from 2 to 40° in 20 with a step size of 0.026° and a measuring time of 76 s per step. The PXRD pattern of hydroquinone cocrystal was obtained using synchrotron radiation at ALBA's beamline BL04-117 MSPD using Mythen detector. The wavelength, 0.6196 Å, was selected with a double-crystal Si (111) 118 monochromator and determined from a Si640d NIST standard (a = 5.43123 Å) measurement. The 119 120 diffractometer is equipped with a socalled MYTHEN detector system especially suited for time-resolved experiments. The capillary of 0.7 mm containing the sample was rotated during data collection to 121 122 improve diffracting particle statistics. The data acquisition time was 10 min per pattern, and the final

treated data are the addition of 10 acquisitions to attain a very good signal-tonoise ratio over the angular range $0.5-43.6^{\circ}$ (20) at 100 K.

125

126 2.2.2. Single Crystal X-ray Diffraction. Ago-AA Form II. MAR345 diffractometer with an image plate

- 127 detector was used. Intensity data were collected with graphite monochromatized MoK α radiation (λ =
- 128 0.71073 Å) using a ϕ -scan technique. The structures were solved by direct methods, using the SHELXS
- 129 computer program, and refined by full-matrix least-squares method with the SHELX97 computer
- 130 program. Ago-HQ Form I, Ago-OA Form I and Ago-PA. A D8 Venture system equipped with a
- 131 Multilayer monochromator and a Mo microfocus ($\lambda = 1.54178$ Å) was used. The structures were solved
- using the Bruker SHELXTL Software Package and refined using SHELXL.11
- 133

2.2.3. Differential Scanning Calorimetry (DSC). Differential scanning calorimetry was carried out by
 means of a Mettler-Toledo DSC-822e calorimeter. Experimental conditions: aluminum crucibles of 40
 µL volume, atmosphere of dry nitrogen with 50 mL/min flow rate, and heating rate of 10 °C/min. The

calorimeter was calibrated with indium of 99.99% purity. All the melting points reported have been

- 138 measured under these conditions.
- 139

140 2.2.4. Thermogravimetric Analysis (TGA). Thermogravimetric analyses were performed with all solids

- obtained during the screening to detect the presence of solvates on a Mettler-Toledo TGA-851e
- thermobalance. Experimental conditions: alumina crucibles of 70 μL volume, atmosphere of dry

143 nitrogen with 50 mL/min flow rate, and heating rate of 10 °C/min.

144

2.2.5. Miller. Liquid-assisted grinding experiments were performed with a Retsch ball mill MM 2000
equipped with two metal vessels, each with four 2 mL cavities. Two tungsten balls (diameter 3 mm)

147 were used in each experiment which was performed at 30 Hz for 15 or 30 min.

- 148
- 149
- 150

151 **3. RESULTS AND DISCUSSION**

152

153 **3.1. Bibliographic Search.** Recently, a search of polymorphic cocrystals that contain at least two neutral organic solid components under ambient conditions has been reported showing 110 systems.5 154 We have updated this information by analyzing the Cambridge Structural Database (CSD, November 155 156 2014), and we have found 128 polymorphic cocrystals (Refcodes included in Supporting Information (SI)), involving 165 different compounds. Among them, 41 compounds (a list can be found in SI) appear 157 in more than one system. These data suggest that it is quite likely from a statistical point of view that 158 compounds forming polymorphic cocrystals with one coformer will do the same with other coformers. 159 160 This tendency is observed in the case of agomelatine as we report in the present study two polymorphic cocrystals with acetic acid and hydroquinone. 161

3.2. Cocrystal Screening. Agomelatine contains a secondary amide group which can be involved in supramolecular heterosynthons with different complementary functional groups such as carboxylic acids, alcohols, esters, amides, etc. as it has been demonstrated by the cocrystals previously reported.9,10 Therefore, based on this information, we have investigated a number of coformers (see SI). After performing drop grinding experiments with equimolar amounts of agomelatine and each coformer, the previously described cocrystals in the literature were detected together with new cocrystals with hydroquinone, acetic acid, pyruvic acid, and oxalic acid.

169 Results of liquid-assisted grinding experiments between agomelatine and hydroquinone and oxalic acid with one drop of four different solvents (water, acetonitrile, ethyl acetate, and cyclohexane) are shown in 170 Table 1. As it can be seen, two different cocrystals for each coformer were obtained depending on the 171 solvent used in liquid-assisted grinding experiments. It has been previously reported that liquid-assisted 172 grinding methodology can provide a successful means of controlling the polymorphic outcome of 173 174 cocrystallization. For example, in the case of caffeine and glutaric acid, the addition of some drops of a 175 nonpolar solvent (such as n-hexane, cyclohexane, or heptane) to equimolar quantities of caffeine and glutaric acid resulted in cocrystal form I. Conversely, the addition of some drops of a more polar 176 177 solvent, including chloroform, dichloromethane, acetonitrile, and water, yielded cocrystal form II with identical secondary architecture.12 A similar observation has been reported for the polymorphic 178 179 cocrystals of caffeine and anthranilic acid (both polymorphs exhibit the same synthon) where the dipole moment and the functional group of the solvent seemed to play a role, and only if the solvent molecule 180 had a high dipole moment, was cocrystal form II formed, nitromethane being an exception despite its 181 182 high dipole moment.13 Another example shows a high degree of solvent polarity specificity for the 183 grinding experiments between 5-fluorouracil and 4-hydroxybenzoic acid.14 In the case of the new 184 agomelatine cocrystals the solvent also plays a major role in the solid form outcome of grinding experiments with hydroquinone, but it is rather irrelevant with oxalic acid. However, a correlation 185 186 between the polarity of the solvent and the solid form obtained is not clear, showing that the cocrystallization kinetic landscape of a compound can be a very complex issue influenced by many 187 188 factors. Regarding the oxalic acid cocrystals, Form II of the Ago-OA cocrystal was always obtained as a 189 mixture with Form I, and attempts to obtain it by using other methodologies such as slurries or crystallizations were unsuccessful, so it has not been further studied. 190

191 The relative stability between both polymorphs of the hydroquinone cocrystal has been determined.

192 Suspensions of an equimolar mixture of Ago-HQ Form I and Form II in diisopropylether or toluene

transformed into pure Form II after 3 days, showing that Form I is metastable at room temperature.

194 Moreover, DSC analysis of Form I shows its melting at 81 °C with simultaneous crystallization of Form

195 II which melts at 93 °C, suggesting that both polymorphs are monotropically related since the highest

melting form is the most stable one at room temperature (Figure 2).16

- 197 Regarding acetic acid and pyruvic acid coformers, which unlike hydroquinone and oxalic acid are
- 198 liquids at room temperature, grinding experiments between agomelatine and one drop of each coformer
- 199 were performed. A new acetic acid cocrystal different from the previously reported9 and a mixture of
- 200 Agomelatine Form II and pyruvic acid cocrystal were obtained, respectively. Both cocrystals were also
- 201 obtained by slow crystallization from a solution of agomelatine in either acetic acid or pyruvic acid.
- 3.3. Crystal Structures Analysis. 3.3.1. Hydroquinone Polymorphic Cocrystals. Two polymorphs of
 the hydroquinone cocrystal with 1:1 stoichiometry were obtained. Form I was solved by single crystal
 XRD. However, attempts to grow quality crystals of Form II were unsuccessful. Thus, the resolution of
 its crystal structure was achieved by using the direct space methodology.
- 206 The structure has been determined using synchrotron X-ray powder diffraction data obtained in the high-
- resolution powder diffraction end station of the MSPD beamline in Alba. The right data have been
- obtained with the sample in a 0.7 glass capillary, at 100 K, with a wavelength of 0.6194 Å using the
 Mythen detector. Attempts to index high resolution powder diffraction data with Cu Kα laboratory X-
- ray powder diffraction data at room temperature has not been successful. The 100 K synchrotron powder
- diffraction data was perfectly indexed to an orthorhombic cell of about 1830 Å3 by means of
- 212 Dicvol04,17 and the space group was perfectly determined to be P212121 from the systematic absences.
- 213 The asymmetric unit being one molecule (1:1 agomelatine/hydroquinone stoichiometry), Z = 4, the
- crystal structure was determined by direct space methodologies starting from a molecular model
- optimized with the commercial software SPARTAN by means of the program FOX18 with the parallel
- tempering algorithm. Some constraints were introduced to FOX, considering aromatic rings as rigid
- 217 groups. Several trials of 20 million runs were performed. The refinement of the structure has been
- 218 performed by the Rietveld method using FullProf.19 Rwp = 3.54%, Chi2 = 80 (compared to Le Bail fit:
- 219 Rwp = 2.24%, Chi2 = 32) Figure 3 depicts the final Rietveld plot.
- Synthon polymorphism occurs when the primary synthons in the forms are different20 as it is the
 present case of the two polymorphs of the agomelatine-hydroquinone cocrystal.
- In Form I, hydroquinone molecules form chains in a cis conformation, with the hydroxyl groups of each
- 223 molecule acting simultaneously as H-bond acceptor and donor. Layers of agomelatine molecules are
- intercalated between the hydroquinone chains stabilized through H-bonds involving both CO and NH
- 225 groups of each molecule of agomelatine.
- On the other hand, in Form II only the carbonylic oxygen of each agomelatine is involved in a hydrogenbond with hydroquinone (Figure 4).
- 228 Interestingly, the agomelatine molecules do not interact with other agomelatine molecules in the usual
- amide/amide selfassembling motif observed in the three agomelatine polymorphs (Refcodes:
- 230 WERNOW,8 WERNOW01,9 and WERNOW029). In Form II, again hydroquinone molecules adopt the
- cis conformation forming similar self-assembling chains as in Form I, but the most relevant difference
- with respect to Form I is that a NH $\cdots\pi$ interaction is established between the agomelatine amidic proton
- and the hydroquinone aromatic ring (NH…centroid distance of 2.58 Å). Moreover, the naphthalene
- 234 moieties of agomelatine establish two CH $\cdots\pi$ interactions (CH \cdots centroid distances of 2.53 and 2.83 Å),
- 235 Figure 5.
- 236 The hydrogen bonding interaction between the amide group and the aromatic ring is less frequent in
- 237 crystal structure of proteins, where the amide/amide is much more predominant, the NH $\cdots\pi$ interaction
- in proteins being first reported by Perutz in 1986.21 However, ab initio calculations revealed that the
- 239 NH $\cdots \pi$ interaction, although weaker than a conventional hydrogen bond, is still significant (up to 3.5
- kcal/mol,22 so as Hunter suggested "H-bonding to the face of aromatic rings may play a significant role
- in molecular recognition phenomena in different environments"),23 as it has been demonstrated in Form

- 242 II, where the strong amide/amide interaction is not observed, while $CH\cdots\pi$ and $NH\cdots\pi$ interactions are 243 relevant.
- Another remarkable difference between both polymorphs is the different orientation of the selfassembled hydroquinone chains. While in Form I chains are almost perpendicular, in Form II they are parallel (Figure 6). Moreover, while in the chains of Form II the hydroquinone molecules are coplanar, in those of Form I hydroquinone molecules show some displacement from coplanarity. Interestingly, in both polymorphs, the hydroquinone molecules adopt the cis configuration, which is unusual according to the reported search in the CSD in which the 87.5% of the 137 analyzed containing hydroquinone structures were in the trans configuration.24 The absence of inversion centers in both crystal structures
- 251 can explain the cis configuration observed in the hydroquinone molecule of both polymorphs and give 252 additional support to the hypothesis by Pidcock et al.25 in the sense that the molecules with inversion
- 253 centers tend to preserve it mainly in centrosymmetric crystal structures.
- 254 3.3.2. Pyruvic Acid Cocrystal. The pyruvic acid cocrystal was also solved by single crystal XRD. The 255 structure of the pyruvic acid cocrystal shows a hydrogen-bond interaction pattern following the expected 256 hierarchical order between the best donor and the best acceptor of both agomelatine and pyruvic acid, 257 forming ribbons with an alternate amide/acid supramolecular synthon. Moreover, the pyruvic acid cis 258 conformation allows the two carbonylic oxygens to point toward the NH proton in an equidistant way 259 (NH:::OC distance of 2.32 Å) (Figure 7)
- 259 (NH···OC distance of 2.32 Å) (Figure 7).
- Interestingly, the crystal structure can be described as hydrogen-bonded aggregates of self-assembledunits formed by two agomelatine and two pyruvic acid molecules. The most remarkable issue of these
- 262 units is that they are kept together by the combination of two different kind of interactions: classical
- amide/carboxylic acid hydrogen bond together with the less frequent $\pi \cdots \pi$ interaction between the
- naphthalene rings and the carbonyl groups of pyruvic acid. It has been previously demonstrated through
- ab initio quantum mechanical calculations26 that parallel C+O/aromatic ring interactions are favorable
- with centroid-oxygen distances of around 3.0–3.5 Å. Although in the pyruvic acid cocrystal these
- distances are slightly longer (3.58 and 3.67 Å, Figure 8) the almost perfect parallel stacking confirms
- this aromatic interaction observed, to some extent, in the crystal structure of proteins.
- 269 3.3.3. Acetic Acid Polymorphic Cocrystals. A new polymorph of the acetic acid cocrystal with 1:1
- stoichiometry has been obtained. Form I had been previously described in the literature,9 and Form II
- was solved by single crystal XRD. Both polymorphs show the same hydrogen-bond interactions
- following the expected hierarchical order between the best donor and the best acceptor of both
- agomelatine and acetic acid. However, while in Form I the amide and carboxylic acid groups form right-
- hand cooperative helices through the alternation of NH…O and OH…O hydrogen bonds, in Form II the
 same interaction is topologically structured in ribbons (Figure 9). Helixes of Form I are interconnected
- 276 through CH $\cdots\pi$ interactions (CH \cdots centroid distance of 2.97 Å) in an alternated zigzag arrangement of
- agomelatine molecules, while layers in Form II are connected through $CH \cdots \pi$ interactions
- 278 (CH…centroid distance of 2.68 Å) between the acetic acid methyl group and the aromatic face of
- agomelatine (Figure 10).
- 280 Moreover, in Form II the parallel C+O/aromatic ring interaction is also observed with a
- 281 centroid–oxygen distance of 3.56 Å.
- 282 3.3.4. Oxalic Acid Cocrystals. A new oxalic acid cocrystal has been identified during the screening. Its
- crystal structure solved by means of single crystal XRD shows a 2:1 stoichiometry. The analysis of the
- structure reveals that oxalic acid displays a conformation with both carboxylic groups in a perpendicular
- fashion with a 2-fold axis passing through the center of the molecule, which enables four molecules of

- 286 agomelatine to surround it, resembling a calix and establishing strong hydrogen-bonding interactions (Figure 11). 287
- 288 This supramolecular aggregate is repeated thanks to the dual donor/acceptor ability of the amide group,
- 289 which forms ribbons of alternate acid/amide interacting groups (Figure 12). Again and in a similar way
- 290 as in the cocrystal with hydroquinone, the naphthalene moieties of agomelatine establish two longer
- 291 CH··· π interactions (CH···centroid distances of 2.89 and 3.24 Å).
- 292 3.3.5. Hydrogen Bonding Synthons of Agomelatine Cocrystals. Yan et al.10 in their paper about
- agomelatine cocrystals in 2012 presented a scheme showing the possible hydrogen bonding synthons 293
- 294 involving the secondary amide group of this API with different functional groups such as amide,
- carboxylic acid, alcohol, and ester of possible coformers. As a summary, we have analyzed the synthons 295 exhibited in each of the 11 cocrystals of agomelatine (Figure 13).
- 296
- 297 Coformers with carboxylic acid as a unique functional group (acetic acid and oxalic acid) as well as
- pyruvic acid (which contains an additional carbonyl group) exhibit synthons II and III. Synthon I occurs 298
- 299 in urea and isonicotinamide cocrystals as expected for coformers with amide functional groups.
- 300 Cocrystals with ethylene glycol and hydroquinone, which contain alcohols, exhibit synthons V and VI.
- 301 However, a new synthon NH $\cdots\pi$ between the amide and the aromatic group (synthon VII) is observed in
- Ago-HQ Form II, instead of synthon VI. Moreover, coformers with two different functional groups such 302
- 303 as glycolic acid (carboxylic acid and alcohol) and methyl-4-hydroxybenzoate (ester and phenol) exhibit
- synthons involving both functional groups. In the case of glycolic acid, synthons III and VI are formed, 304 whereas for methyl-4- hydroxybenzoate, synthons IV and V are observed. Cocrystals are ideally suited
- 305 306 to study competition between different supramolecular heterosynthons. In both cocrystals, synthons are
- 307 formed between the best H-bond acceptor (alcohol vs carboxylic acid and ester vs phenol) and the best
- 308 H-bond donor (carboxylic acid vs alcohol) as expected according to Hunter's hydrogen bonding
- 309 parameters.27,28
- 310
- 311

313 4. CONCLUSIONS

314

- The present study is focused on extending the knowledge about the multicomponent forms of the drug compound agomelatine. New cocrystals with hydroquinone and several carboxylic acids have been
- discovered through an intensive cocrystal screening, and their crystal structures were solved by means of
- direct space methods together with single crystal X-ray diffraction data. Our results reveal the existence
- of polymorphism at least in two of the new cocrystals showing important differences regarding the type
- 320 of intermolecular interactions involved in the crystal, which convert agomelatine in another case to
- enrich the list of compounds showing cocrystal polymorphism and at the same time contribute to
- 322 dismantle the belief that cocrystals are less prone to exhibit polymorphism than single component
- 323 crystals.

324

326 AUTHOR INFORMATION

- 327 Corresponding Authors
- 328 *(R.P.) Tel. + 34 93 4034656. Fax. + 34 93 4037206. E-mail: <u>rafel@ccit.ub.edu</u>.
- 329 *(C.P.) E-mail: <u>cris@ccit.ub.edu</u>.
- 330
- 331


332 REFERENCES


334	(1)	Cruz-Cabeza, A. J.; Reutzel-Edens, S. M.; Bernstein, J. Chem. Soc. Rev. 2015, 44, 8619-8635.
554	(1)	Gruz Gubeza, A. 5., Reduzer Edens, S. M., Bernstein, S. Chem. Soc. Rev. 2015, 11, 0015 0055.


- 335 (2) Stahly, G. P. Cryst. Growth Des. 2007, 7, 1007–1026.
- 336 (3) Butterhof, C.; Bärwinkel, K.; Senker, J.; Breu, J. CrystEngComm 2012, 14, 6744–6749.
- 337 (4) Clarke, H. D.; Arora, K. K.; Bass, H.; Kavuru, P.; Ong, T. T.; Pujari, T.; Wojtas, L.; Zaworotko,
 338 M. J. Cryst. Growth Des. 2010, 10, 2152–2167.
- 339 (5) Aitipamula, S.; Chow, P. S.; Tan, R. B. H. CrystEngComm 2014, 16, 3451–3465.
- 340 (6) Lemmerer, A.; Adsmond, D. A.; Esterhuysen, C.; Bernstein, J. Cryst. Growth Des. 2013, 13, 3935–3952.
- 342 (7) Taylor, D.; Sparshatt, A.; Varma, S.; Olofinjana, O. BMJ 2014, 348, g1888.
- 343 (8) Tinant, B.; Declercq, J.-P.; Poupaert, J. H.; Yous, S.; Lesieur, D. Acta Crystallogr., Sect. C: C
 344 ryst. Struct. Commun. 1994, 50, 907–910.
- 345 (9) Zheng, S.-L.; Chen, J.-M.; Zhang, W.-X.; Lu, T.-B. Cryst. Growth Des. 2011, 11, 466–471.
- 346 (10) Yan, Y.; Chen, J.-M.; Geng, N.; Lu, T.-B. Cryst. Growth Des. 2012, 12, 2226–2233.
- 347 (11) Sheldrick, G. M. Acta Crystallogr., Sect. A: Found. Crystallogr. 2008, 64, 112–122.
- 348 (12) Trask, A. V.; Motherwell, W. D. S.; Jones, W. Chem. Commun. 2004, 890–891.
- 349 (13) Fischer, F.; Scholz, G.; Benemann, S.; Rademann, K.; Emmerling, F. CrystEngComm 2014, 16,
 350 8272–8278.
- 351 (14) Li, S.; Chen, J.-M.; Lu, T.-B. CrystEngComm 2014, 16, 6450–6458.
- 352 (15) Solvent property parameters: Gu, C.-H.; Li, H.; Gandhi, R. B.; Raghavan, K. Int. J. Pharm.
 353 2004, 283, 117–125.
- 354 (16) Barbas, R.; Prohens, R.; Puigjaner, C. J. Therm. Anal. Calorim. 2007, 89, 687–692.
- 355 (17) Boultif, A.; Louer, D. J. Appl. Crystallogr. 1991, 24, 987.
- 356 (18) Favre-Nicolin, V.; Cerny, R. J. Appl. Crystallogr. 2002, 35, 734–743.
- 357 (19) Rodriguez-Carvajal, J. Phys. B 1993, 192, 55–69.
- 358 (20) Jetti, R. K. R.; Boese, R.; Sarma, J. A. R. P.; Reddy, L. S.; Vishweshwar, P.; Desiraju, G. R.
 359 Angew. Chem., Int. Ed. 2003, 42, 1963–1967.
- 360 (21) Perutz, M. F.; Fermi, G.; Abraham, D. J.; Poyart, C.; Bursaux, E. J. Am. Chem. Soc. 1986, 108, 1064–1078.
- 362 (22) Steiner, T.; Koellner, G. J. Mol. Biol. 2001, 305, 535–557.

363	(23)	Adams, H.; Carver, F. J.; Hunter, C. A.; Osborne, N. J. Chem. Commun. 1996, 2529-2530.
364 365	(24)	Clausen, H. F.; Chevallier, M. S.; Spackman, M. A.; Iversen, B.B. New J. Chem. 2010, 34, 193–199.
366 367	(25)	Pidcock, E.; Motherwell, W. D. S.; Cole, J. C. Acta Crystallogr., Sect. B: Struct. Sci. 2003, 59, 634–640.
368 369	(26)	Jain, A.; Purohit, C. S.; Verma, S.; Sankararamakrishnan, R. J.Phys. Chem. B 2007, 111, 8680–8683.
370	(27)	Etter, M. C. Acc. Chem. Res. 1990, 23, 120–126.
371	(28)	Hunter, C. A. Angew. Chem., Int. Ed. 2004, 43, 5310-5324.
372		
373		

374	Legends to figures
375	
376	Figure 1. Chemical structure of agomelatine.
377	
378	Figure 2. DSC of agomelatine-hydroquinone cocrystals.
379	
380	Figure 3. Results from powder XRD analysis of Form II of hydroquinone/agomelatine cocrystal: (left)
381	Final Rietveld plot for the crystal structure refinement. Agreement factors: $Rwp = 3.54\%$, $Rp = 2.51\%$,
382	(right) Le Bail fit plot. Agreement factors: $Rwp = 2.24\%$, $Rp = 1.46\%$. Each plot shows the
383	experimental powder XRD profile (red + marks), the calculated powder XRD profile (black solid line),
384	and the difference profile (blue, lower line). Tick marks indicate peak positions.
385	
386	Figure 4. Amide/phenol hydrogen-bond interactions between agomelatine and hydroquinone in Form I
387	(a) and Form II (b).
388	
389	Figure 5. (a) NH··· π interaction between the amide and the electron density on the face of the
390	hydroquinone ring in Form II and (b) $CH \cdots \pi$ interactions between the naphthalene moieties in Form II.
391	
392	Figure 6. Different arrangement of hydroquinone ribbons in Form II (a) and Form I (b).
393	
394	Figure 7. Ribbon arrangement of agomelatine pyruvic acid cocrystal. Agomelatine structure has been
395	truncated.
396	
397 398	Figure 8. Self-assembled units of agomelatine and pyruvic acid.
398	Figure 9. Helicoidal topology of Form I (a) and ribbon arrangement of Form II (b) of acetic acid
400	cocrystals.
401	
402	Figure 10. CH $\cdots\pi$ interactions in Form I (a) and in Form II (b) of acetic acid cocrystals.
403	Figure 10. Cit <i>x</i> interactions in Form I (<i>a</i>) and in Form II (<i>b</i>) of accide acid coorystals.
404	Figure 11. Molecules of agomelatine surrounding oxalic acid in the 2:1 cocrystal. Agomelatine methoxy
405	groups have been omitted for clarity.
406	
407	Figure 12. Ribbon arrangement of agomelatine oxalic acid cocrystal.
408	
409	Figure 13. Hydrogen bonding synthons present in agomelatine cocrystals.
410	















FIGURE 5.
 FIGURE 5.
 FIGURE 5.
 (a) (b)















(a)




















Ester














Aromatic



solvent	e	x	results with hydro quinone	results with coalic acid
water	78.36	1.09	Ago-HQ Form I	Ago-OA Form I + Ago- OA Form II ^b
ace to nitrile	35.69	075	Ago-HQ Form II	Ago-OA Form I ^b
ethyl acetate	5.99	0.55	Ago-HQ Form II	Ago-OA Form 1 ^b
cyclohexane	2.02	0.00	Ago-HQ Form I	Ago-OA Form 1 ^b

"e: dielectric constant; n: polarity. ^bOxalic acid was also obtained together with Ago-OA cocrystals.

Table 2. Crystal Data and Structure Refinement Parameters for the Different Forms of Agomelatine Cocrystals

structure	Ago-HQ Form I	Ago-HQ Form II	Ago-AA Form II	Ago-OA	Ago-PA
empirical formula	$\mathrm{C}_{15}\mathrm{H}_{17}\mathrm{NO}_{27}\mathrm{C}_{6}\mathrm{H}_{6}\mathrm{O}_{2}$	C ₁₃ H ₁₀ NO ₂ , C ₆ H ₆ O ₂	C ₁₇ H ₂₁ NO ₄	2(C ₁₃ H ₁₇ NO ₂), C ₂ H ₂ O ₄	C18H21NO3
formula weight	353.40	3.53.40	303.35	576.63	331.36
temperature (K)	106(2)	100	293(2)	302	90(2)
wavelength (Å)	0.71073	0.6196	0.71073	1.54178	0.71073
crystal system	monoclinic	orthorhombic	orthombic	monoclinic	monoclinic
space group	F2,	P212121	Pana	C2	C2/c
a, b, c (Å)	10.8611(15) 28.563(4) 12.0118(17)	21.202.50(14) 12.04722(7) 7.15198(5)	14.224(7) 7.062(3) 16.345(5)	27.8783(17) 7.5821(6)19.7562(14)	18.2641(13), 15.5402(11), 14.6089(17)
α, β, γ (deg)	90, 100.318(5), 90	90°, 90°, 90°	90°, 90°, 90°	90, 133.745(4), 90	90, 126.779(2), 9
volume (Å3)	36661(9)	1826.84(2)	1641.9(12)	30168(4)	33199(5)
Z, density (cak) (Mg/m ³)	8, 1.281	4	4/1.227	4/1.270	8, 1.326
absorption coefficient (mm ⁻¹)	0.088		0.087	0.753	0.097
F(000)	1504		648	1224	1408
crystal size (mm3)	0.583 × 0.468 × 0.431		0.2 × 0.1 × 0.1	0.16 × 0.13 × 0.09	0.14 × 0.12 × 0.0
θ range for data collection (deg)	2.2.37-26.371	2.00-43.58	1.898-30.815	3.10-58.89	2.62-25.10
imiting indices	$-13 \le k \le 13$		$-18 \le h \le 18$	$-30 \le h \le 30$	$-21 \le h \le 21$
and the second second	$-35 \le k \le 35$		$-8 \le k \le 8$	$-8 \le k \le 8$	$-18 \le k \le 18$
	$-15 \le l \le 15$		$-21 \le l \le 21$	$-21 \le l \le 21$	$-17 \le l \le 17$
reflections collected/unique	73951/14971 [R(int) = 0.0770]		11977/2208 [R(int) = 0.0638]	4774/2958 [R(int) = 0.0879]	20241/2947 [R(int) = 0.044
completeness to θ (%)	99.9		95.9	869	99.5
absorption connection	a mic mpirical from equivalents		empirical	semiempifical from equivalents	semiempińcal from equivalents
max and min transmission	0.7459 and 0.6481		0.5 and 0.5	0.7516 and 0.5587	0.961 and 0.943
refinement method	full-matrix least-squares on F ²	Rietweld	full-matrix least- squares on F ²	fall-matrix least-squares on F ¹	full-matrix least- squares on P ²
data/parameters	14971/249/977	2406/87/131	2208/0/152	2958/8/380	2947/0/220
goodness-of - fit on Ft	1.009	Chi = 8.94	1.181	0.962	1.046
final R indices $[I > 2\sigma(I)]$	$R_1 = 0.0410,$ $sR_2 = 0.0890$		$R_1 = 0.0539,$ $wR_2 = 0.1478$	$R_1 = 0.0641, wR_2 = 0.1015$	R ₁ = 0.0532, wR ₂ = 0.1243
R indices (all data)	$R_i = 0.0616,$ $xR_2 = 0.0988$	Rwp = 3.54, Chi2 = 80	$R_1 = 0.0675,$ $wR_2 = 0.1585$	$R_1 = 0.1904, wR_2 = 0.1364$	R ₁ = 0.0716, wR ₂ = 0.1417
largest diff. peak and hole (e-Å-3)	0.171 and -0.207		0.134 and -0.145	0.173 and -0.193	0.480 and -0.247
CCDC	1048038	1058734	1048035	1060576	1048039